What is a stock summary page? Click here for an overview.
Business Description
Avadel Pharmaceuticals PLC
NAICS : 325414
SIC : 2834
ISIN : IE00BDGMC594
Share Class Description:
AVDL: ADRCompare
Compare
Traded in other countries / regions
AVDL.USAAWK.Germany Index Membership
Russell 2000Russell 3000 IPO Date
1996-06-07Description
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 43.3 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.1 | |||||
| Beneish M-Score | 1.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 35.7 | |||||
| 3-Year EPS without NRI Growth Rate | 25.8 | |||||
| 3-Year FCF Growth Rate | 28 | |||||
| 3-Year Book Growth Rate | -16.9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 32.76 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 11.41 | |||||
| 9-Day RSI | 26.55 | |||||
| 14-Day RSI | 34.58 | |||||
| 3-1 Month Momentum % | -28.09 | |||||
| 6-1 Month Momentum % | -39.43 | |||||
| 12-1 Month Momentum % | -51.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.75 | |||||
| Quick Ratio | 2.33 | |||||
| Cash Ratio | 1.51 | |||||
| Days Inventory | 344.12 | |||||
| Days Sales Outstanding | 60.16 | |||||
| Days Payable | 264.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.1 | |||||
| Shareholder Yield % | 4.12 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.97 | |||||
| Operating Margin % | -25.07 | |||||
| Net Margin % | -28.88 | |||||
| FCF Margin % | -27.74 | |||||
| ROE % | -63.43 | |||||
| ROA % | -30.05 | |||||
| ROIC % | -75.98 | |||||
| 3-Year ROIIC % | -281.78 | |||||
| ROC (Joel Greenblatt) % | -173.89 | |||||
| ROCE % | -32.32 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 78.3 | |||||
| PS Ratio | 4.1 | |||||
| PB Ratio | 9.35 | |||||
| Price-to-Tangible-Book | 12.2 | |||||
| EV-to-EBIT | -16.96 | |||||
| EV-to-Forward-EBIT | 9.49 | |||||
| EV-to-EBITDA | -18.24 | |||||
| EV-to-Forward-EBITDA | 8.97 | |||||
| EV-to-Revenue | 3.84 | |||||
| EV-to-Forward-Revenue | 2.56 | |||||
| EV-to-FCF | -13.83 | |||||
| Price-to-Net-Current-Asset-Value | 16 | |||||
| Earnings Yield (Greenblatt) % | -5.9 | |||||
| FCF Yield % | -6.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AVDL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Avadel Pharmaceuticals PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 169.117 | ||
| EPS (TTM) ($) | -0.52 | ||
| Beta | 1.83 | ||
| 3-Year Sharpe Ratio | 0.38 | ||
| 3-Year Sortino Ratio | 0.69 | ||
| Volatility % | 50.06 | ||
| 14-Day RSI | 34.58 | ||
| 14-Day ATR ($) | 0.364028 | ||
| 20-Day SMA ($) | 8.1695 | ||
| 12-1 Month Momentum % | -51.8 | ||
| 52-Week Range ($) | 7.07 - 19.09 | ||
| Shares Outstanding (Mil) | 96.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Avadel Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Avadel Pharmaceuticals PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Avadel Pharmaceuticals PLC Frequently Asked Questions
What is Avadel Pharmaceuticals PLC(AVDL)'s stock price today?
The current price of AVDL is $7.20. The 52 week high of AVDL is $19.09 and 52 week low is $7.07.
When is next earnings date of Avadel Pharmaceuticals PLC(AVDL)?
The next earnings date of Avadel Pharmaceuticals PLC(AVDL) is 2025-05-08 Est..
Does Avadel Pharmaceuticals PLC(AVDL) pay dividends? If so, how much?
Avadel Pharmaceuticals PLC(AVDL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers